Express Pharma

Approval of first interchangeable biosimilar insulin to increase competition with payer contracts: GlobalData

While patients will be increasingly prescribed Viatris/Biocon’s Semglee over Sanofi’s Lantus due to its competitive pricing, Semglee’s commercial success will be limited due to the declining use of first-generation long-acting insulins

0 382

When it comes to insulin choice, price is currently the biggest barrier, as insulin brand preference is primarily determined not by a doctor, but through payer contracts with pharma companies, according to GlobalData. The company, in a statement, said that while patients will be increasingly prescribed Viatris/Biocon’s Semglee (biosimilar insulin glargine-yfgn) over Sanofi’s Lantus (insulin glargine) due to its competitive pricing, Semglee’